Sepsis is a common diagnose in the intensive care population, burdened with a high mortality. The systemic inflammatory reaction underlying the development of septic organ dysfunction can be modeled using Gram-negative bacterial lipopolysaccharide, endotoxin. This thesis used a porcine endotoxemic experimental sepsis model to address clinical questions difficult to answer in clinical trials; furthermore a model of secondary sepsis was developed. No additional effect on the development of renal dysfunction by tobramycin was found, indicating that a single dose of tobramycin does not further compromise renal function in inflammatory-induced acute kidney injury. Antiendotoxin treatment had no measurable effect on TNF-α-mediated toxicity once the inflammatory cascade was activated. There was an effect on the leukocyte response that was associated with improvements in respiratory function and microcirculation, making it impossible to rule out fully the beneficial effect of this strategy. However, the effects were limited in relation to the magnitude of the endotoxin concentration reduction and the very early application of the antiendotoxin measure. The lungs stood out compared to the other organ systems as having a threshold endotoxin dose for the protective effect of endotoxin tolerance. As to the development of circulatory and renal dysfunction, tolerance to endotoxin was evident regardless of the endotoxin pre-exposure and challenge dose. There was a temporal variation of endotoxin tolerance that did not follow changes in plasma TNF-α concentrations and maximal tolerance was seen very early in the course. More pronounced endotoxin tolerance at the time of maximum tolerance was associated with a more marked hyperdynamic circulation, reduced oxygen consumption and thrombocytopenia eighteen hours later. It might be of interest to use the experimental model of long-term endotoxemia followed by a second hit, which has been designed to resemble an intensive care setting, for the study of treatment effects of immunomodulating therapies in secondary sepsis. / Paper 3, previous title as submitted: "Compartmentalization of organ endotoxin tolerance in a porcine model of secondary sepsis"

Objetivo: Avaliar a influência da infecção por Pseudomonas aeruginosa formadora de biofilme na penetração pulmonar da tobramicina através da modelagem populacional dos dados de plasma e microdialisado em animais sadios e infectados. Metodologia: A pneumonia foi desenvolvida através de inoculação de P. aeruginosa (cepa PA14) pela via intratraqueal (109 UFC/mL) a ratos Wistar. Sete dias após a inoculação os animais infectados (n = 5) receberam tobramicina 10 mg/kg i.v. bolus. Animais saudáveis (n = 6) foram utilizados como controle. As concentrações livres pulmonares foram coletadas por microdiálise (sonda CMA/20). As sondas de microdiálise foram calibradas in vitro através de diálise e retrodiálise e in vivo utilizando retrodiálise. A ligação da tobramicina às proteínas plasmáticas foi determinada por microdiálise. As concentrações do fármaco nas amostras foram determinadas por cromatografia líquida em tandem com espectrometria de massas (CLAE-EM/EM) utilizando metodologia validada. Os parâmetros farmacocinéticos foram determinados por abordagem não-compartimental (Phoenix®) e modelagem populacional (popPK) (Monolix®). Resultados e Discussão: A recuperação relativa (RR) das sondas foi independente da concentração de tobramicina e inversamente proporcional ao fluxo de perfusão. A RR determinada in vivo foi de 27,64 % ± 7,70 para animais sadios e 24,47 % ± 1,66 para animais infectados. A ligação às proteínas plasmáticas foi de 11,3 ± 1,9%. A infecção com formação de biofilme não alterou a farmacocinética plasmática da tobramicina, entretanto reduziu em cerca de 70% a penetração pulmonar do fármaco. As concentrações plasmáticas e teciduais foram simultaneamente descritas por um modelo farmacocinético populacional de dois compartimentos, tanto em animais sadios como infectados. A infecção, utilizada como covariável categórica, permitiu descrever as alterações no volume do compartimento periférico e na constante de eliminação do compartimento central devido à infecção. Conclusões: As concentrações plasmáticas da tobramicina, utilizadas para ajuste posológico, superestimam as concentrações ativas no pulmão infectado. O modelo popPK descrito permite a previsão das concentrações livres pulmonares da tobramicina em pulmão infectado, podendo auxiliar na otimização da terapia de pneumonias com P. aeruginosa formadora de biofilme. / Objective: To evaluate the influence of biofilm-forming Pseudomonas aeruginosa infection on tobramycin lung penetration by population pharmacokinetic modeling of plasma and microdialysate data in healthy and infected rats. Methodology: The infection was developed by intratracheal inoculation (109 CFU/mL) of P. aeruginosa (PA14 strain) to Wistar rats. In order to determine plasma and tissue concentrations, seven days after the inoculation the infected animals (n = 5) received tobramycin 10 mg/kg i.v. bolus dose via femoral vein. A healthy group (n = 6) was used as control. Free lung concentrations were determined in microdialysate samples obtained using CMA/20 probes. Microdialysis probes were calibrated in vitro by dialysis and retrodialysis and in vivo by retrodialysis. Tobramycin plasma protein binding was determined by microdialysis. Plasma and tissue concentrations were quantified by a developed and validated liquid chromatography in tandem with mass spectrometry (LC-MS/MS) method. Compartmental and non-compartmental analyses were carried out by Monolix™ and Phoenix™ software, respectively. Results and Discussion: Microdialysis probes relative recovery was independent of the tobramycin concentration and is inversely proportional to the perfusion flow rate investigated. The in vivo probe recovery was 27.64 % ± 7.70 (healthy rats) and 24.47 % ± 1.66 (infected rats). The plasma protein binding was 11.3 ± 1.9%. The biofilm-forming lung infection did not alter tobramycin plasma pharmacokinetics, however, reduced lung penetration in about 70%. The plasma and tissue concentrations-time profiles were simultaneously described by a two compartment popPK model in healthy and infected animals. The infection process, used as categorical covariate allowed describing the changes observed in the volume of the peripheral compartment and in constant rate of elimination from the central compartment. Conclusions: Tobramycin plasma concentrations, used for dosing adjustments, overestimate active concentrations in infected lung. The described popPK model allows predicting free tobramycin lung concentrations in infected lung and could be useful to optimize the treatment of pneumonia caused by biofilm-forming P. aeruginosa with this drug.

Objetivo: Avaliar a influência da infecção por Pseudomonas aeruginosa formadora de biofilme na penetração pulmonar da tobramicina através da modelagem populacional dos dados de plasma e microdialisado em animais sadios e infectados. Metodologia: A pneumonia foi desenvolvida através de inoculação de P. aeruginosa (cepa PA14) pela via intratraqueal (109 UFC/mL) a ratos Wistar. Sete dias após a inoculação os animais infectados (n = 5) receberam tobramicina 10 mg/kg i.v. bolus. Animais saudáveis (n = 6) foram utilizados como controle. As concentrações livres pulmonares foram coletadas por microdiálise (sonda CMA/20). As sondas de microdiálise foram calibradas in vitro através de diálise e retrodiálise e in vivo utilizando retrodiálise. A ligação da tobramicina às proteínas plasmáticas foi determinada por microdiálise. As concentrações do fármaco nas amostras foram determinadas por cromatografia líquida em tandem com espectrometria de massas (CLAE-EM/EM) utilizando metodologia validada. Os parâmetros farmacocinéticos foram determinados por abordagem não-compartimental (Phoenix®) e modelagem populacional (popPK) (Monolix®). Resultados e Discussão: A recuperação relativa (RR) das sondas foi independente da concentração de tobramicina e inversamente proporcional ao fluxo de perfusão. A RR determinada in vivo foi de 27,64 % ± 7,70 para animais sadios e 24,47 % ± 1,66 para animais infectados. A ligação às proteínas plasmáticas foi de 11,3 ± 1,9%. A infecção com formação de biofilme não alterou a farmacocinética plasmática da tobramicina, entretanto reduziu em cerca de 70% a penetração pulmonar do fármaco. As concentrações plasmáticas e teciduais foram simultaneamente descritas por um modelo farmacocinético populacional de dois compartimentos, tanto em animais sadios como infectados. A infecção, utilizada como covariável categórica, permitiu descrever as alterações no volume do compartimento periférico e na constante de eliminação do compartimento central devido à infecção. Conclusões: As concentrações plasmáticas da tobramicina, utilizadas para ajuste posológico, superestimam as concentrações ativas no pulmão infectado. O modelo popPK descrito permite a previsão das concentrações livres pulmonares da tobramicina em pulmão infectado, podendo auxiliar na otimização da terapia de pneumonias com P. aeruginosa formadora de biofilme. / Objective: To evaluate the influence of biofilm-forming Pseudomonas aeruginosa infection on tobramycin lung penetration by population pharmacokinetic modeling of plasma and microdialysate data in healthy and infected rats. Methodology: The infection was developed by intratracheal inoculation (109 CFU/mL) of P. aeruginosa (PA14 strain) to Wistar rats. In order to determine plasma and tissue concentrations, seven days after the inoculation the infected animals (n = 5) received tobramycin 10 mg/kg i.v. bolus dose via femoral vein. A healthy group (n = 6) was used as control. Free lung concentrations were determined in microdialysate samples obtained using CMA/20 probes. Microdialysis probes were calibrated in vitro by dialysis and retrodialysis and in vivo by retrodialysis. Tobramycin plasma protein binding was determined by microdialysis. Plasma and tissue concentrations were quantified by a developed and validated liquid chromatography in tandem with mass spectrometry (LC-MS/MS) method. Compartmental and non-compartmental analyses were carried out by Monolix™ and Phoenix™ software, respectively. Results and Discussion: Microdialysis probes relative recovery was independent of the tobramycin concentration and is inversely proportional to the perfusion flow rate investigated. The in vivo probe recovery was 27.64 % ± 7.70 (healthy rats) and 24.47 % ± 1.66 (infected rats). The plasma protein binding was 11.3 ± 1.9%. The biofilm-forming lung infection did not alter tobramycin plasma pharmacokinetics, however, reduced lung penetration in about 70%. The plasma and tissue concentrations-time profiles were simultaneously described by a two compartment popPK model in healthy and infected animals. The infection process, used as categorical covariate allowed describing the changes observed in the volume of the peripheral compartment and in constant rate of elimination from the central compartment. Conclusions: Tobramycin plasma concentrations, used for dosing adjustments, overestimate active concentrations in infected lung. The described popPK model allows predicting free tobramycin lung concentrations in infected lung and could be useful to optimize the treatment of pneumonia caused by biofilm-forming P. aeruginosa with this drug.

No description available.

Yes / TOBI® is a recently marketed preservative and sulphate free tobramycin formulation approved by FDA for maintenance therapy for patient with cystic fibrosis. The performance of selected recent nebuliser delivery systems has been assessed using the developed method to determine the optimum combinations to deliver approved tobramycin inhaled solution (TOBI)®. A simple, sensitive and specific high performance liquid chromatographic method has been developed and used to quantitative determination of the aminoglycoside tobramycin following pre-column derivatisation with phenylisocyanate (PIC). The reaction time was 10 min at 80º C and the resulting derivative was stable for five days at room temperature. The quantitative performance of the assay was further improved by using another aminoglycoside (neomycin) as internal standard. The stable resulting PIC-tobramycin derivative was separated using a HPLC 5μm Columbus C18 column (150x4.60 mm i.d, Phenomenex). The mobile phase was consisted of acetonitrile-glacial acetic acid-water (450:5:545, v/v/v) and ultraviolet detection at (240 nm). The proposed method showed good validation data. The standard curve was linear (n=5) at seven different concentrations, ranging from 20 to 140μg/ml and the correlation coefficient (R2) of the regression line was 0.9995. The limit of detection (LOD) and limit of quantitation (LOQ) were 0.86μg/ml and 2.62μg/ml, respectively. The relative standard deviation (RSD %) was less than 0.6% for intra-day assay (n=5) and 2.5% for inter-day assay (n=5). A number of nebuliser performance comparison studies have been demonstrated for aerosolise TOBI® to choice the optimum combination produces high repirable inhaled mass of tobramycin. The objective of this study was to evaluate the performance of recent nebuliser delivery systems to nebulise approved tobramycin inhaled solution (TOBI)®.

Yes / Background Chronic infections with Pseudomonas aeruginosa are a leading cause of morbidity in patients with cystic fibrosis (CF). Tobramycin nebulizer solution (TNS) is indicated for maintenance therapy in CF patients. TOBI® is a tobramycin nebulizer solution (TNS) approved by FDA for maintenance therapy for patient with CF. Adherence to recommended therapy in CF has always been a challenge and new generation nebulizers are increasingly used “off label” to reduce the time required for inhalation, potentially improving patient compliance. Objectives To assess the performance of selected recent nebulizer delivery systems for determination the optimum combinations to deliver TOBI®. Using the relative lung bioavailability of TOBI® to the lungs in healthy volunteers, following inhalation from selected nebulizer delivery systems, using a urinary pharmacokinetics method. In vitro aerodynamic characteristics of the nebulized dose were also determined. Methods Serial urine samples were collected from 12 healthy volunteers up to 24 h post-inhalation of TOBI® inhaled solution following delivery by Pari LC Plus®, Sidestream®, NE-U22-E Omron® and Aeroneb® Go nebulizers. In vitro aerodynamic characteristics of the nebulized dose were also determined according to the CEN (Committee European de Normalization) method. Results The mean (SD) relative lung bioavailability from Pari LC Plus®, Sidestream®, Omron®, and Aeroneb® Go nebulizers was 4.9 (0.5), 3.9 (0.5), 7.1 (1.3), and 7.7 (0.7) %, respectively. The mean (SD) mass median aerodynamic diameter (MMAD) of the drug particles from the same systems was 2 (0.2), 2 (0.2), 1.2 (0.03) and 2.0 (0.1) μm, and the corresponding fine particle doses (FPD) were 2.2 (0.23), 1.5 (0.2), 3.44 (0.3) and 2.8 (0.3) mg. Conclusion The data obtained from in-vitro and in-vivo studies reflect poor relative lung bioavailability of tobramycin following jet nebulization.

[pt] Os aminoglicosídeos (AMG) pertencem a uma classe de antibióticos eficazes no tratamento de infecções provocadas por micro-organismos Gram-negativos e Gram-positivos. Ototoxidade, nefrotoxidade e alterações musculares são efeitos colaterais provocados pelo uso dessas substâncias, implicando na importância do controle das medicações com uso de métodos analíticos práticos para a rotina, sensíveis e seletivos. As estruturas dos AMG não possuem grupos cromóforos que habilitem a medição de atividade óptica direta, dessa maneira, os métodos descritos na literatura para determinação dos mesmos, normalmente, fazem uso da derivatização química implicando em alta morosidade, elevados custos e toxicidade (dados os reagentes utilizados) em tais métodos. No presente trabalho, propõe-se a utilização de nanopartículas de ouro (AuNPs) como sondas analíticas para a determinação espectrofotométrica de AMG, tirando-se proveito do efeito de ressonância plasmônica na superfície de AuNPs. Investigou-se o potencial analítico do uso de dispersões aquosas de AuNPs como sondas para a determinação de tobramicina (TBR), neomina (NEO), gentamicina (GENTA), canamicina (CANA), estreptomicina (EST) e amicacina (AMIC), observando-se resultados promissores para todos os AMG citados, excerto para a EST. No caso da TBR, foi desenvolvido um método analítico para a sua determinação em soluções oftálmicas. As curvas analíticas foram construídas a partir do monitoramento da luz transmitida em 529 nm ou 681 nm. O monitoramento do sinal analítico em 529 nm apresentou uma faixa linear entre 6,5 x 10-9 mol L-1 a 1,6 x 10-7 mol L-1 com boa linearidade (R2=0,9943) e limite de detecção (LD) igual a 6,2 x 10-9 mol L-1. O monitoramento do sinal analítico em 681 nm apresentou uma faixa linear entre 4,4 x 10-9 mol L-1 a 1,6 x 10-7 mol L-1 com boa linearidade (R2=0,9949) e valor de LD igual a 3,8 x 10-9 mol L-1. O método mostrou-se robusto em uma faixa de pH entre 2,6 e 4,5, durante 120 min. O método apresentou precisão satisfatória e demonstrou seletividade com relação a outro AMG, STP, e com relação aos excipientes presentes nas amostras analisadas. Obtiveram-se percentuais de recuperação para as amostras (simuladas e reais de soluções oftálmicas) de 104,0 a 123,1 por cento e de 101,1 a 123,6 por cento, para o monitoramento do sinal analítico em 529 nm e 681 nm, respectivamente. Utilizando-se um método comparativo para validar esses resultados, verificou-se através do teste t-student que os percentuais de recuperação encontrados através das sondas de AuNPs e através do método comparativo foram estatisticamente iguais. Estudos com saliva de pacientes em tratamento com TBR indicam o potencial da sonda para a análise de fluidos biológicos. / [en] Aminoglycosides (AMG) belong to a class of antibiotics effective for the treatment of infections caused by Gram-negative and Gram-positive micro-organisms. Ototoxicity, nephrotoxicity and muscle disorders are side effects of using these substances, implying the importance of controlling the use of pharmaceutical formulations based on AMG with practical analytical methods for routine, sensitive and selective. The molecular structures of the AMG does not present any relevant chromophores groups that enable direct measurement of their optical activity, thus, the methods described in the literature for determining it normally to use of chemical derivatization implying high delays, high costs and toxicity (dice reagents used) in such methods. The studies present in this dissertation, it is proposed to use of gold nanoparticles (AuNPs) as analytical probes for spectrophotometric determination of AMG, by exploration of the resonance Plasmon effect on the surface of AuNPs. Was investigated the analytical potential of aqueous dispersions of AuNPs as probes for the determination of tobramycin (TBR) neomina (NEO), gentamicin (GENTA), kanamycin (CANA), streptomycin (EST) and amikacin (AMIC). Promising results were found for all AMG cited excerpt EST. In the case of TBR, an analytical method for its determination in ophthalmic solutions was proposed. The analytical curves were constructed by monitoring the transmitted light at 529 nm or 681 nm. The monitoring of the analytic signal in 529 nm yielding a linear range from 6.5 x 10-9 mol L-1 to 1.6 x 10-7 mol L-1 with good linearity (R2= 0.9943) and the limit of detection (LOD) equal to 6.2 x 10-9 mol L-1. The monitoring of the analytic signal in 681 nm yielding a linear range from 4.4 x 10-9 mol L-1 to 1.6 x 10-7 mol L-1 with good linearity (R2= 0.9949) and the LOD equal to 3.8 x 10-9 mol L-1. The method showed to be robust in a pH range between 2.6 and 4.5, for 120 min. The method showed satisfactory accuracy and demonstrated selectivity with respect to other AMG, EST, and with respect to excipients present in the samples analyzed. Yielded percentage recoveries for samples (simulated and real ophthalmic solutions) from 104.0 to 123.1 percent and from 101.1 to 123.6 percent, for the monitoring of the analytical signal at 529 nm and 681 nm, respectively. Using a comparative method to validate these results, it was found through the t-student test that the percentage recovery found through the AuNPs probes and the comparative method were statistically equal. Studies in saliva from patients under TBR treatment indicated the potential of the probe for the analysis of biological fluids.

La fibrose kystique (FK) est une maladie qui affecte principalement les systèmes respiratoires, digestifs et reproducteurs et rend les personnes atteintes plus susceptibles aux surinfections bronchiques et aux exacerbations pulmonaires. Le dosage initial et les ajustements de dose des antibiotiques sont difficiles en raison des altérations pharmacocinétique (PK), la grande variabilité PK et l'émergence de résistance aux antibiotiques dans cette population. En guise d’introduction, le premier chapitre de ce mémoire présente la pathologie de la fibrose kystique, des principes de base en pharmacologie et en modélisation compartimentale. Le deuxième chapitre présente une revue systématique de la littérature sur les modèles PK de population des antibiotiques développés dans la population FK adulte. Cette étude a mis en évidence les facteurs démographiques et cliniques ayant le plus d'impact sur la PK des antibiotiques en FK. Par exemple, le poids corporel maigre était la covariable la plus fréquemment utilisée pour estimer les paramètres PK des β-lactamines. Le troisième chapitre montre comment les modèles PK de population peuvent être utilisés pour proposer des stratégies de dosage alternatives aux cliniciens. Les résultats ont montré que la normalisation des doses de tobramycine par la taille (à une dose de 3,4 mg/cm) permet d'obtenir des concentrations maximales et minimales de tobramycine adéquates pour un patient médian. Le quatrième chapitre présente une évaluation méthodologique de l’impact du temps de prélèvement à 8h post-dose sur la performance prédictive de modèles PK de population pour la tobramycine. Il a été démontré que les paramètres PK du deuxième compartiment sont biaisés lorsqu’estimés en utilisant des concentrations simulées issues de temps de prélèvement divergents du modèle analysé. Le cinquième chapitre illustre le développement et l’évaluation d'un nomogramme de doses initiales pour la tobramycine basé sur la taille. Les doses dérivées du nomogramme entraînent une réduction significative de la variabilité des concentrations maximales prédites par rapport à ce qui est observé en clinique, ce qui pourrait potentiellement améliorer les issues cliniques en FK. Ce mémoire a donc démontré l'importance et la pertinence de la modélisation et des simulations dans un contexte clinique afin d’améliorer la prise en charge des patients atteints de FK. / Cystic fibrosis (CF) is a progressive, hereditary disease that primarily affects the respiratory, digestive, and reproductive systems and makes patients more likely to develop bronchial bacterial infections, and subsequently experience acute pulmonary exacerbations. Effective antibiotic use is in part responsible for the decreased respiratory burden observed over the past decades. However, initial dosing and dose adjustments of antibiotics, particularly of tobramycin, is challenging due to altered pharmacokinetics (PK), high PK variability, and emergence of antibiotic resistance. The first chapter of this dissertation presents the pathology of cystic fibrosis, basic principles in pharmacology and compartmental modeling. The second chapter presents a systematic literature review of population PK models of antibiotics developed for adult patients with CF. This study highlighted the demographic and clinical factors most impacting the PK of prescribed antibiotics in this population. For example, lean body weight was the most frequently used covariate for estimating PK parameters of β-lactams. The third chapter of this memoire shows how previously developed population PK models can be leveraged to propose alternative dosing strategies to clinicians. It was found that dose normalization of tobramycin using height rather than body weight at a 3.4 mg/cm dose resulted in tobramycin maximum and residual concentrations within the target range found in published guidelines for a median patient. The fourth chapter presents a methodological evaluation of the impact of 8h post-dose sampling times on the predictive performance of tobramycin population PK models. It was shown that the PK parameters of the second compartment are biased when estimated using simulated concentrations from divergent sampling times of the analyzed model. The fifth chapter shows the development and evaluation of an initial tobramycin dosing nomogram based on height rather than body weight to further individualize antibiotic therapy for CF patients. It was found that doses derived from the proposed nomogram resulted in significantly reduced variability in predicted peak concentrations values in comparison to what is observed in clinical practice, which could potentially improve clinical outcomes for CF patients. This memoire has therefore demonstrated the importance of modeling and simulations in a clinical setting to improve the management of CF in adult patients.

Master of Science / Department of Clinical Sciences / David E. Anderson / Drug delivery systems for time release of recombinant human bone morphogenetic protein-2 (rhBMP-2) and antibiotics in orthopedic surgeries continue to be developed. Recently, a biodegradable novel polymeric matrix has been developed for this purpose. We hypothesized that impregnation of the matrix with rhBMP-2 would enhance bone healing. The objectives of the study were to characterize elution of rhBMP-2 and two antimicrobials (tigecycline, tobramycin) from the matrix, and bone response to the matrix in the presence or absence of rhBMP-2 and antimicrobials. In vitro elution of tigecycline, tobramycin, and rhBMP-2 from the matrix was investigated. Drug concentration in media were measured on days 1-6, 8, 10, 13, 15, 17, 21, 25, 28, and 30 using high pressure liquid chromatography/mass spectrometry/mass spectrometry (HPLC/MS/MS; antimicrobials) and ELISA (rhBMP-2). In vivo testing was done using a unicortical defect created into each tibia of twenty adult goats. Animals were randomly assigned to one of 5 groups: 1) control (untreated defect); 2) matrix; 3) matrix+ antimicrobials (tigecycline+tobramycin); 4) matrix+rhBMP-2; and 5) matrix+antimicrobials+rhBMP-2. Plasma concentration of tigecycline and tobramycin and serum concentration of rhBMP-2 were measured by the above techniques on days 1-7, 9, 11, 13, 15, 17, 22, 26, and 30. Bone response was assessed on days 0, 14, and 30 using radiographic scoring and dual energy X-ray absorptiometry (bone mineral density [BMD]). After euthanasia on day 30, histomorphologic analyses of the bone defects were done. Categorical variables were analyzed using a generalized linear model, and continuous variables using an ANOVA with P < 0.05 considered significant. In vitro elution was characterized by a rapid release on day 1 followed by a slow release until day 30 for both antimicrobials and rhBMP-2. Plasma antimicrobial concentrations showed continued release throughout the study period. Serum rhBMP-2 concentration, radiographic scores and BMD were not significantly different between groups. Periosteal and endosteal reaction surface areas were significantly greater surrounding the defects in group 4 (matrix+rhBMP-2). There was no significant difference between the groups for the percent of bone filling the defect. The matrix served as an appropriate antimicrobial and rhBMP-2 delivery system and successfully stimulated bone production when rhBMP-2 was present.

Using a semi-PBPK modeling/quantitative meta-analysis approach, this project investigated what factors affect pulmonary and systemic exposures of Budesonide (BUD), Tobramycin (TOB), and Ciprofloxacin (CIP) after inhalation: Three structurally different pulmonary disposition models were developed for each drug, including pulmonary absorption (all three), excretion (TOB and CIP) and sequestration (TOB) in a peripheral and central lung compartment. Systemic disposition parameters were estimated using available human mean plasma (cp(t)) and sputum (cs(t)) concentration profiles after IV administration, and GI absorption parameters were estimated from these profiles after oral administration. Pulmonary disposition parameters were estimated from cp(t) and cs(t) profiles after inhalation using various devices along with their published pulmonary deposition characteristics. Appropriate covariate models accounted for effects of Cystic Fibrosis on the systemic disposition/GI absorption for TOB and CIP. Monte Carlo Simulations (MCS) were used to optimize parameters and validate the final models and parameter spaces against published data. Despite limited available data, especially cs(t) for BUD and CIP (after IV administration), the point estimates for the final model parameters were mechanistically plausible for all three drugs and consistent with their known differences in physicochemical and ADME properties. Model predictions adequately described the observed cp(t) and cs(t) profiles as well as exposure metrics across studies. As the most lipophilic drug, BUD showed the fastest pulmonary absorption rates and highest Fpul (83%). TOB, a very hydrophilic drug, exhibited (intracellular) pulmonary sequestration, resulting in slow pulmonary absorption and excretion and low Fpul (10%). CIP - as zwitterion - showed relatively slow pulmonary absorption and excretion, leading to low Fpul (8%); pulmonary excretion accounted for 27% of CIP overall elimination. Results of a formal parameter sensitivity analysis demonstrated that, for all three drugs, after inhalation, (1) their systemic exposures (cp(t)) depend primarily on CLtot along with Fpul/sequestration combined with Foral; (2) increasing pulmonary exposures (cs(t)) can be accomplished by slowing down pulmonary absorption rates (kca) and/or slowing down mucociliary clearance from the lungs into the GI tract (kcm) – affirming the overall hypothesis guiding the project.